Mortality differences among patients with in-hospital ST-elevation myocardial infarction.


Journal

Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 20 07 2020
revised: 30 09 2020
accepted: 04 10 2020
pubmed: 8 11 2020
medline: 10 8 2021
entrez: 7 11 2020
Statut: ppublish

Résumé

In-hospital ST-elevation myocardial infarction (STEMI) is associated with a higher mortality rate than out-of-hospital STEMI. Quality measures and universal protocols for treatment of in-hospital STEMI do not exist, likely contributing to delays in recognition and treatment. To analyze differences in mortality among three subsets of patients who develop in-hospital STEMI. This was a multicenter, retrospective observational study of patients who developed in-hospital STEMI at six United States medical centers between 2008 and 2017. Patients were stratified into three groups: (1) cardiac, (2) periprocedure, or (3) noncardiac/nonpostprocedure. Outcomes examined include time from electrocardiogram (ECG) acquisition to cardiac catheterization lab arrival (ECG-to-CCL) and survival to discharge. We identified 184 patients with in-hospital STEMI (mean age 68.7 years, 58.7% male). Group 1 (cardiac) patients had a shorter average ECG-to-CCL time (69 minutes) than group 2 (periprocedure, 215 minutes) and group 3 (noncardiac/nonpostprocedure, 199 minutes). Compared to group 1, survival to discharge was lower for group 2 (OR 0.33, P = .102) and group 3 (OR 0.20, P = .016). After adjusting for prespecified covariates, the relationship between group and survival showed a similar trend but did not reach statistical significance. Patients who develop in-hospital STEMI in the context of a preceding procedure or noncardiac illness appear to have longer reperfusion times and higher in-hospital mortality than patients admitted with cardiac diagnoses. Larger studies are warranted to further investigate these observations. Health systems should place an increased emphasis on developing quality metrics and implementing quality improvement initiatives to improve outcomes for in-hospital STEMI.

Sections du résumé

BACKGROUND BACKGROUND
In-hospital ST-elevation myocardial infarction (STEMI) is associated with a higher mortality rate than out-of-hospital STEMI. Quality measures and universal protocols for treatment of in-hospital STEMI do not exist, likely contributing to delays in recognition and treatment.
HYPOTHESIS OBJECTIVE
To analyze differences in mortality among three subsets of patients who develop in-hospital STEMI.
METHODS METHODS
This was a multicenter, retrospective observational study of patients who developed in-hospital STEMI at six United States medical centers between 2008 and 2017. Patients were stratified into three groups: (1) cardiac, (2) periprocedure, or (3) noncardiac/nonpostprocedure. Outcomes examined include time from electrocardiogram (ECG) acquisition to cardiac catheterization lab arrival (ECG-to-CCL) and survival to discharge.
RESULTS RESULTS
We identified 184 patients with in-hospital STEMI (mean age 68.7 years, 58.7% male). Group 1 (cardiac) patients had a shorter average ECG-to-CCL time (69 minutes) than group 2 (periprocedure, 215 minutes) and group 3 (noncardiac/nonpostprocedure, 199 minutes). Compared to group 1, survival to discharge was lower for group 2 (OR 0.33, P = .102) and group 3 (OR 0.20, P = .016). After adjusting for prespecified covariates, the relationship between group and survival showed a similar trend but did not reach statistical significance.
CONCLUSIONS CONCLUSIONS
Patients who develop in-hospital STEMI in the context of a preceding procedure or noncardiac illness appear to have longer reperfusion times and higher in-hospital mortality than patients admitted with cardiac diagnoses. Larger studies are warranted to further investigate these observations. Health systems should place an increased emphasis on developing quality metrics and implementing quality improvement initiatives to improve outcomes for in-hospital STEMI.

Identifiants

pubmed: 33159461
doi: 10.1002/clc.23480
pmc: PMC7724232
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1555-1561

Informations de copyright

© 2020 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.

Références

J Am Coll Cardiol. 2006 Jun 6;47(11):2180-6
pubmed: 16750682
J Am Heart Assoc. 2013 Apr 04;2(2):e000004
pubmed: 23557748
Circulation. 2006 May 2;113(17):2152-63
pubmed: 16569790
JAMA. 2012 Feb 22;307(8):813-22
pubmed: 22357832
Circulation. 2014 Mar 18;129(11):1225-32
pubmed: 24389237
J Am Coll Cardiol. 2009 Dec 15;54(25):2423-9
pubmed: 20082933
JAMA. 2014 Nov 19;312(19):1999-2007
pubmed: 25399275
JACC Cardiovasc Interv. 2008 Feb;1(1):97-104
pubmed: 19393152
Nat Rev Cardiol. 2016 Mar;13(3):148-54
pubmed: 26525542
Clin Cardiol. 2020 Dec;43(12):1555-1561
pubmed: 33159461
JAMA Cardiol. 2018 Jun 1;3(6):527-531
pubmed: 29466558

Auteurs

Negeen Shahandeh (N)

University of California Los Angeles, Los Angeles, California, USA.

Xuming Dai (X)

University of North Carolina, Chapel Hill, North Carolina, USA.

Brian Jaski (B)

Sharp Memorial Hospital San Diego, San Diego, California, USA.

Ravi Dave (R)

University of California Los Angeles, Los Angeles, California, USA.

Alice Jacobs (A)

Boston University Medical Center, Boston, Massachusetts, USA.

Ali Denktas (A)

The Michael E. DeBakey VA Medical Center, Houston, Texas, USA.
Baylor College of Medicine, Houston, Texas, USA.

Glenn Levine (G)

Baylor College of Medicine, Houston, Texas, USA.

Daniela Markovic (D)

University of California Los Angeles, Los Angeles, California, USA.

Sidney C Smith (SC)

University of North Carolina, Chapel Hill, North Carolina, USA.

Marcella Calfon Press (MC)

University of California Los Angeles, Los Angeles, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH